Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
- Author
- CERESOLI, G. L1 ; ZUCALI, P. A2 ; SOTO-PARRA, H10 ; DE VINCENZO, F2 ; BRUZZONE, A3 ; LORENZI, E2 ; GIANONCELLI, L2 ; ERCOLI, B2 ; GIORDANO, L11 ; SANTORO, A2 ; MENCOBONI, M3 ; BOTTA, M4 ; GROSSI, F5 ; CORTINOVIS, D6 ; ZILEMBO, N7 ; RIPA, C1 ; TISEO, M8 ; FAVARETTO, A. G9
[1] Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy
[2] Department of Oncology, Humanitas Cancer Center, Rozzano (Milan), Italy
[3] Department of Oncology, Ospedale Villa Scassi, Sampierdarena, ASL 3 Genovese, Genova, Italy
[4] Department of Medical Oncology, Ospedale S. Spirito, Casale Monferrato, Italy
[5] Lung Cancer Unit, National Institute for Cancer Research, Genova, Italy
[6] Department of Medical Oncology, Ospedale San Gerardo, Monza, Italy
[7] Department of Medical Oncology, National Cancer Institute, Milan, Italy
[8] Department of Medical Oncology, Ospedale Maggiore, Parma, Italy
[9] Department of Medical Oncology, Istituto Oncologico Veneto IRCCS, Padova, Italy
[10] Department of Medical Oncology, Ospedale Universitario Vittorio Emanuele, Catania, Italy
[11] Biostatistic Unit, Humanitas Cancer Center, Rozzano (Milan), Italy - Source
British journal of cancer. 2013, Vol 109, Num 3, pp 552-558, 7 p ; ref : 1 p
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- bevacizumab chemotherapy mesothelioma
- Keyword (fr)
- Antiangiogénique Anticancéreux Bévacizumab Cancérologie Carboplatine Chimiothérapie Essai clinique phase II Facteur croissance endothélium vasculaire Immunomodulateur Mésothéliome malin de la plèvre Pémétrexed Traitement de première intention Anti-VEGF Anticorps monoclonal Antifolate Cancer Pathologie de l'appareil respiratoire Pathologie de la plèvre Platine II Complexe Traitement Tumeur maligne
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Bevacizumab Cancerology Carboplatin Chemotherapy Phase II trial Vascular endothelium growth factor Immunomodulator Malignant pleural mesothelioma Pemetrexed First line treatment Monoclonal antibody Antifolate Cancer Respiratory disease Pleural disease Platinum II Complexes Treatment Malignant tumor
- Keyword (es)
- Antiangiogenico Anticanceroso Bevacizumab Cancerología Carboplatino Quimioterapia Ensayo clínico fase II Factor crecimiento endotelio vascular Inmunomodulador Mesotelioma maligno pleural Pemetrexed Tratamiento de primera línea Anticuerpo monoclonal Antifolato Cáncer Aparato respiratorio patología Pleura patología Platino II Complejo Tratamiento Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Pulmonology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27605267
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/bjc.2013.368 
https://dx.doi.org/10.1038/bjc.2013.368
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.368\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"552\";s:8:\"\u0000*\u0000epage\";s:3:\"558\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CERESOLI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"G. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:12:\"ZUCALI, P. A\";i:1;s:13:\"SOTO-PARRA, H\";i:2;s:14:\"DE VINCENZO, F\";i:3;s:11:\"BRUZZONE, A\";i:4;s:10:\"LORENZI, E\";i:5;s:14:\"GIANONCELLI, L\";i:6;s:9:\"ERCOLI, B\";i:7;s:11:\"GIORDANO, L\";i:8;s:10:\"SANTORO, A\";i:9;s:12:\"MENCOBONI, M\";i:10;s:8:\"BOTTA, M\";i:11;s:9:\"GROSSI, F\";i:12;s:13:\"CORTINOVIS, D\";i:13;s:10:\"ZILEMBO, N\";i:14;s:7:\"RIPA, C\";i:15;s:8:\"TISEO, M\";i:16;s:15:\"FAVARETTO, A. G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.368\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"552\";s:8:\"\u0000*\u0000epage\";s:3:\"558\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CERESOLI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"G. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:12:\"ZUCALI, P. A\";i:1;s:13:\"SOTO-PARRA, H\";i:2;s:14:\"DE VINCENZO, F\";i:3;s:11:\"BRUZZONE, A\";i:4;s:10:\"LORENZI, E\";i:5;s:14:\"GIANONCELLI, L\";i:6;s:9:\"ERCOLI, B\";i:7;s:11:\"GIORDANO, L\";i:8;s:10:\"SANTORO, A\";i:9;s:12:\"MENCOBONI, M\";i:10;s:8:\"BOTTA, M\";i:11;s:9:\"GROSSI, F\";i:12;s:13:\"CORTINOVIS, D\";i:13;s:10:\"ZILEMBO, N\";i:14;s:7:\"RIPA, C\";i:15;s:8:\"TISEO, M\";i:16;s:15:\"FAVARETTO, A. G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.368\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.368\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"552\";s:8:\"\u0000*\u0000epage\";s:3:\"558\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CERESOLI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"G. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:12:\"ZUCALI, P. A\";i:1;s:13:\"SOTO-PARRA, H\";i:2;s:14:\"DE VINCENZO, F\";i:3;s:11:\"BRUZZONE, A\";i:4;s:10:\"LORENZI, E\";i:5;s:14:\"GIANONCELLI, L\";i:6;s:9:\"ERCOLI, B\";i:7;s:11:\"GIORDANO, L\";i:8;s:10:\"SANTORO, A\";i:9;s:12:\"MENCOBONI, M\";i:10;s:8:\"BOTTA, M\";i:11;s:9:\"GROSSI, F\";i:12;s:13:\"CORTINOVIS, D\";i:13;s:10:\"ZILEMBO, N\";i:14;s:7:\"RIPA, C\";i:15;s:8:\"TISEO, M\";i:16;s:15:\"FAVARETTO, A. G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.368\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"552\";s:8:\"\u0000*\u0000epage\";s:3:\"558\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CERESOLI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"G. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:12:\"ZUCALI, P. A\";i:1;s:13:\"SOTO-PARRA, H\";i:2;s:14:\"DE VINCENZO, F\";i:3;s:11:\"BRUZZONE, A\";i:4;s:10:\"LORENZI, E\";i:5;s:14:\"GIANONCELLI, L\";i:6;s:9:\"ERCOLI, B\";i:7;s:11:\"GIORDANO, L\";i:8;s:10:\"SANTORO, A\";i:9;s:12:\"MENCOBONI, M\";i:10;s:8:\"BOTTA, M\";i:11;s:9:\"GROSSI, F\";i:12;s:13:\"CORTINOVIS, D\";i:13;s:10:\"ZILEMBO, N\";i:14;s:7:\"RIPA, C\";i:15;s:8:\"TISEO, M\";i:16;s:15:\"FAVARETTO, A. G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.368\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"552\";s:8:\"\u0000*\u0000epage\";s:3:\"558\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CERESOLI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"G. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:12:\"ZUCALI, P. A\";i:1;s:13:\"SOTO-PARRA, H\";i:2;s:14:\"DE VINCENZO, F\";i:3;s:11:\"BRUZZONE, A\";i:4;s:10:\"LORENZI, E\";i:5;s:14:\"GIANONCELLI, L\";i:6;s:9:\"ERCOLI, B\";i:7;s:11:\"GIORDANO, L\";i:8;s:10:\"SANTORO, A\";i:9;s:12:\"MENCOBONI, M\";i:10;s:8:\"BOTTA, M\";i:11;s:9:\"GROSSI, F\";i:12;s:13:\"CORTINOVIS, D\";i:13;s:10:\"ZILEMBO, N\";i:14;s:7:\"RIPA, C\";i:15;s:8:\"TISEO, M\";i:16;s:15:\"FAVARETTO, A. G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:117:\"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
